Table I.
In vitro activity of Volasertib against PPTP cell lines.
| Cell Line | Histotype | rIC50 (nM) | Panel rIC50/Line rIC50 | Ymin (%) (Observed) | Ymin (%) (Model Based) | Relative In/Out (Observed Ymin) |
|---|---|---|---|---|---|---|
| RD | Rhabdomyosarcoma | 16.5 | 0.85 | 1.7 | 0.0 | −69% |
| Rh41 | Rhabdomyosarcoma | 6.9 | 2.04 | 7.7 | 11.4 | −65% |
| Rh18 | Rhabdomyosarcoma | 135.2 | 0.10 | 20.2 | 0.0 | −55% |
| Rh30 | Rhabdomyosarcoma | 8.2 | 1.71 | 11.0 | 12.8 | −34% |
| BT-12 | Rhabdoid | 55.7 | 0.25 | 13.1 | 15.2 | 5% |
| CHLA-266 | Rhabdoid | 47.5 | 0.30 | 9.2 | 10.1 | −65% |
| TC-71 | Ewing sarcoma | 13.8 | 1.02 | 0.1 | 0.0 | −94% |
| CHLA-9 | Ewing sarcoma | 17.7 | 0.80 | 0.5 | 0.0 | −85% |
| CHLA-10 | Ewing sarcoma | 17.3 | 0.82 | 1.9 | 0.0 | −70% |
| CHLA-258 | Ewing sarcoma | 37.4 | 0.38 | 6.1 | 5.8 | −84% |
| SJ-GBM2 | Glioblastoma | 11.8 | 1.19 | 1.9 | 0.0 | −81% |
| NB-1643 | Neuroblastoma | 15.5 | 0.91 | 4.4 | 5.5 | −79% |
| NB-EBc1 | Neuroblastoma | 34.5 | 0.41 | 0.7 | 0.0 | −97% |
| CHLA-90 | Neuroblastoma | 24.6 | 0.58 | 14.9 | 15.4 | −47% |
| CHLA-136 | Neuroblastoma | 6.0 | 2.35 | 1.9 | 3.3 | −93% |
| NALM-6 | ALL | 12.7 | 1.11 | 0.0 | 0.0 | −99% |
| COG-LL-317 | ALL | 11.3 | 1.25 | 0.0 | 0.0 | −100% |
| RS4;11 | ALL | 7.8 | 1.82 | 0.8 | 0.0 | −95% |
| MOLT-4 | ALL | 12.2 | 1.16 | 0.0 | 0.0 | −100% |
| CCRF-CEM (1) | ALL | 11.5 | 1.23 | 0.0 | 0.0 | −100% |
| CCRF-CEM (2) | ALL | 14.2 | 1.00 | 0.0 | 0.0 | −99% |
| Kasumi-1 | AML | 14.1 | 1.00 | 1.2 | 3.5 | −96% |
| Karpas-299 | ALCL | 14.9 | 0.95 | 0.5 | 0.0 | −93% |
| Ramos-RA1 | NHL | 13.0 | 1.08 | 0.0 | 0.0 | −100% |
| Median | 14.1 | 1.00 | 1.5 | 0.00 | −89% | |
| Minimum | 6.0 | 0.10 | 0.0 | 0.00 | −100% | |
| Maximum | 135.2 | 2.35 | 20.2 | 15.38 | 5% |